Injection Lipolysis Market By Drug Type(Deoxycholic Acid, Phosphatidylcholine, Others), By Treatment Site(Facial Fat Deposits, Submental Fat, Upper Arm Fat, and Others), and by Region and Companies Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032.

Injection Lipolysis Market Overview:

The Injection Lipolysis Market is projected to reach a valuation of USD 16.99 Bn by 2032 at a CAGR of 9.5%, from USD 9 Bn in 2021.

Injection lipolysis is a non-invasive procedure involving multiple fine injections of active ingredients into the treatment area to liquefy, dissolve, and eliminate the number of fat cells. This can be an effective treatment to remove stubborn fat pockets in the face, neck, and body. Such treatments are generally relatively simple in comparison to surgery and may require multiple sessions, with no post-operative downtime or anesthesia being needed.

The global injection lipolysis market is segmented based on – Drug Type, Treatment Site, End-User, and Region. This market’s segmentation is listed below:

By Drug Type

• Deoxycholic Acid
• Phosphatidylcholine
• Others

By Treatment Site

• Facial Fat Deposits
• Submental Fat
• Upper Arm Fat
• Abdominal Fat
• Thighs Fat
• Knee Fat
• Buttock Fat
• Others

By End-User

• Hospitals
• Dermatology & Cosmetic Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Dynamics

Growth in obese populations across the globe due to unhealthy lifestyles is expected to spur injection lipolysis market growth prospects. According to the world health statistics report presented by the World Health Organization (WHO), globally, one in six individuals is obese. And, this ratio is increasing gradually, which is also expected to create significant growth opportunities for the injection lipolysis market.

According to the data presented by the World Health Organization (2016), there are around 2 billion overweight adults, and of those 650 million are considered to be affected by obesity. This means that 40% of adult women and 39% of adult men, aged 18 or older, are overweight, with a 13% obese ratio.

The prevalence of obesity has more than tripled since 1975. If current trends continue, it is projected that more than 2.7 billion adults will be overweight, with over 1 billion of them being affected by obesity, and 177 Mn adults being severely overweight by 2025.

Increasing geriatric populations, and the acceptance of different body fat reduction procedures in developed and developing countries, are anticipated to influence this target market’s economic growth. Moreover, a greater focus on aesthetics for beautification or improving appearances among the female population is a major factor driving target market growth.

Additionally, the increasing demand for body contouring surgical and non-surgical treatments are anticipated to further propel this target market’s projected growth.

Technological advancements in non-invasive and minimally invasive procedures are expected to boost industry expansion prospects. A recently observed trend is that several industry players are developing new radiofrequency laser lipolysis, cryolipolysis, and ultrasound procedures.

For instance, in September 2019, Cutera Inc. received approval from Health Canada for its truSculpt iD system to reduce belly fat as well as to sculpt various other areas in lesser duration of time.

However, some side effects of injection lipolysis procedures include pain, skin rash, swelling, and a stinging sensation. In addition, the availability of alternative fat breakdown techniques may also hamper the economic growth of the global injection lipolysis industry to a certain extent.

Competitive Landscape

Major players in the target market are

• AbbVie Inc.
• INTROPHARMA
• Shandong Chenguang Biotechnology Co. Ltd.
• Shijiazhuang Tiantian Technology Co. Ltd.
• NEXUS PHARMA Co. Ltd.
• Hebei Chefhi International Trade Co. Ltd.
• Others

For the XXXXX Market research study, the following years have been considered to estimate the market size: